CNTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Context Therapeutics Inc (CNTX) is not a strong buy for a beginner, long-term investor at this time. The stock has shown a significant regular market decline (-8.76%) with no strong technical or proprietary trading signals to suggest an immediate recovery or growth potential. While analysts have raised the price target to $7, the company's financial performance remains weak, with no revenue growth and negative net income. Additionally, there are no recent news catalysts or significant trading trends to support a bullish sentiment.
The MACD is negative and expanding (-0.0482), RSI is neutral at 22.338, and moving averages are converging, indicating no clear upward momentum. The stock is trading near its support level (S1: 2.324) with resistance levels at R1: 2.855 and R2: 3.019, suggesting limited upside potential in the short term.
Analyst Piper Sandler raised the price target to $7 from $4, citing lower operating expenses and pipeline updates.
The stock experienced a significant regular market decline (-8.76%) with no recent news or trading trends to support a recovery. Financial performance remains weak with no revenue growth and negative net income.
In Q4 2025, revenue remained at $0 with no growth. Net income improved to -$13,025,607 (up 289.65% YoY), and EPS improved to -0.14 (up 250% YoY), but the company remains unprofitable.
Piper Sandler maintains an Overweight rating and raised the price target to $7 due to improved cost structure and pipeline updates.
